유전체 의학 시장 : 시장 예측 - 제품 및 서비스별, 기술별, 유전체 의학 접근별, 검사 유형별, 검체 유형별, 임상 용도별, 최종 사용자별 및 지역별 분석(-2034년)

According to Stratistics MRC, the Global Genomic Medicine Market is accounted for $49.7 billion in 2026 and is expected to reach $180.7 billion by 2034 growing at a CAGR of 17.5% during the forecast period. The genomic medicine market focuses on healthcare solutions that utilize genetic and genomic information to enhance disease detection, risk assessment, treatment selection, and patient management. By combining technologies such as genome sequencing, molecular diagnostics, CRISPR-based gene editing, and computational data analysis, genomic medicine enables more personalized clinical care. These approaches help clinicians identify disease-related genetic mutations, tailor therapies to individual patients, and support informed medical decisions. The market includes sequencing instruments, diagnostic assays, bioinformatics platforms, genomic analysis services, and precision medicine applications serving hospitals, clinical laboratories, academic research organizations, and biopharmaceutical companies.

Market Dynamics:

Driver:

Increasing Prevalence of Genetic and Rare Diseases

A rising burden of inherited and uncommon genetic disorders is encouraging greater use of genomic medicine in healthcare. Traditional diagnostic techniques frequently fail to identify the underlying genetic causes of these diseases, making genomic analysis an important clinical tool. Genetic testing enables physicians to detect pathogenic variants, establish accurate diagnoses, and design individualized treatment strategies. Medical researchers use genomic information to understand disease biology and identify new therapeutic targets. These capabilities support improved patient management while encouraging healthcare providers and pharmaceutical developers to expand the use of genomic technologies in addressing complex genetic conditions.

Restraint:

High Cost of Genomic Testing and Advanced Technologies

The expense associated with genomic medicine remains a significant challenge because advanced sequencing equipment, computational analysis tools, and laboratory infrastructure require considerable investment. Healthcare organizations must allocate resources for specialized workforce training, quality control, and ongoing system maintenance to deliver accurate genomic services. Comprehensive genetic testing and interpretation also increase overall healthcare costs, reducing accessibility for many patients and providers. Smaller hospitals and laboratories often face financial barriers when adopting these technologies, limiting their ability to integrate genomic medicine into routine clinical practice and slowing its availability across different healthcare systems and regions.

Opportunity:

Expansion of Population Genomics and Preventive Healthcare

The broader implementation of population genomics is creating new opportunities for genomic medicine by supporting disease prevention and personalized health management. Large-scale genetic studies enable researchers and healthcare professionals to identify inherited disease risks, improve screening programs, and guide preventive interventions before symptoms appear. Population-based genomic information also enhances scientific understanding of genetic diversity and disease progression across different communities. Governments, healthcare institutions, and research organizations continue expanding genomic initiatives to strengthen public health strategies. These developments increase the importance of genomic medicine in preventive healthcare and long-term disease management.

Threat:

Misinterpretation of Genetic Information

The possibility of incorrectly analyzing genetic information represents an important threat to genomic medicine. Some genetic variants remain poorly understood, making it difficult for healthcare professionals to determine their clinical relevance with complete confidence. Inaccurate interpretation can affect diagnosis, treatment selection, and patient counseling while reducing confidence in genomic testing outcomes. Differences in laboratory practices, analytical software, and professional expertise further increase interpretation challenges. Continuous updates to genomic databases, specialized training, and validated analytical approaches are essential to reduce errors and support reliable implementation of genomic medicine in clinical practice.

Covid-19 Impact:

The COVID-19 pandemic significantly increased the visibility and application of genomic medicine across healthcare systems by demonstrating the importance of genomic sequencing and molecular analysis in understanding infectious diseases. Healthcare providers, research organizations, and diagnostic laboratories enhanced their genomic capabilities to track viral evolution, improve diagnostic accuracy, and support epidemiological monitoring. Greater collaboration among biotechnology companies, academic institutions, and public health agencies accelerated the integration of genomic technologies into routine healthcare practices. The experience also strengthened laboratory infrastructure, expanded bioinformatics capabilities, and emphasized the long-term role of genomic medicine in disease surveillance, personalized healthcare, and clinical research.

The Sequencing Instruments segment is expected to be the largest during the forecast period

The Sequencing Instruments segment is expected to account for the largest market share during the forecast period because sequencing platforms serve as the core technology supporting genomic medicine across healthcare and life sciences. They enable comprehensive genetic analysis required for diagnosing inherited disorders, cancer profiling, infectious disease research, and personalized treatment planning. Healthcare providers, research organizations, and biotechnology companies depend on these systems to produce reliable genomic information for clinical and scientific applications. Ongoing technological enhancements that improve sequencing efficiency, analytical performance, scalability, and workflow integration continue to reinforce the importance of sequencing instruments throughout the genomic medicine ecosystem.

The Rare Genetic Disorders segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Rare Genetic Disorders segment is predicted to witness the highest growth rate because genomic medicine provides highly accurate tools for detecting inherited diseases that often remain undiagnosed through traditional diagnostic approaches. Advanced sequencing and molecular analysis help clinicians identify genetic abnormalities, guide individualized treatment decisions, and support family risk assessment through genetic counseling. Hospitals, specialty clinics, and diagnostic laboratories are increasingly incorporating genomic testing into routine evaluation of rare diseases. Ongoing improvements in genomic technologies, stronger research collaborations, and broader availability of specialized genetic services continue to expand the role of genomic medicine in managing rare genetic disorders effectively.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, because the region possesses a mature healthcare ecosystem that widely utilizes genomic technologies for disease diagnosis, precision treatment, and biomedical research. Healthcare organizations benefit from sophisticated laboratory infrastructure, experienced genomic specialists, and strong collaboration between research institutes and life sciences companies. The widespread use of sequencing technologies, molecular diagnostics, and bioinformatics platforms supports efficient clinical implementation of genomic medicine. Ongoing commitment to precision healthcare, innovation in genomic research, and strong institutional support continues to position North America as the leading regional market for genomic medicine.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to expanding healthcare infrastructure, increasing adoption of advanced genomic technologies, and growing integration of precision medicine into clinical practice. Countries across the region are strengthening genomic research capabilities through investments in sequencing laboratories, bioinformatics platforms, and translational medicine initiatives. Healthcare providers are increasingly utilizing genomic testing for disease diagnosis, personalized treatment planning, and hereditary disease screening. Collaboration among academic institutions, biotechnology companies, pharmaceutical organizations, and healthcare systems is enhancing access to genomic services, while continuous technological advancements support broader implementation of genomic medicine across diverse clinical applications.

Key players in the market

Some of the key players in Genomic Medicine Market include Illumina, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., QIAGEN N.V., Agilent Technologies, Inc., Pacific Biosciences of California, Inc. (PacBio), Oxford Nanopore Technologies plc, BGI Genomics Co., Ltd., Revvity, Inc., Exact Sciences Corporation, Guardant Health, Inc., Natera, Inc., Myriad Genetics, Inc., GeneDx Holdings Corp., Tempus AI, Inc., NeoGenomics, Inc., Personalis, Inc. and GRAIL, Inc.

Key Developments:

In May 2026, Oxford Nanopore Technologies announced a strategic collaboration with Werfen to support the development of advanced transplant assays.

In May 2026, Illumina strengthened collaborations with governments, health systems, and research institutions to expand population-scale genomics, sovereign data stewardship, and national precision health initiatives.

In January 2026, Thermo Fisher Scientific announced a strategic collaboration with NVIDIA to leverage artificial intelligence for advancing scientific instrumentation and improving laboratory performance.

Product & Services Covered:

• Sequencing Instruments
• Reagents & Consumables
• Bioinformatics Software
• Genomic Testing Services
• Clinical Interpretation Services

Technologies Covered:

• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Sanger Sequencing
• Microarray
• CRISPR Genome Editing
• Fluorescence In Situ Hybridization (FISH)
• Digital PCR (dPCR)
• Long-Read Sequencing

Genomic Medicine Approach Covered:

• Molecular Diagnostics
• Precision Medicine
• Pharmacogenomics
• Gene Therapy
• Gene Editing

Test Types Covered:

• Diagnostic Testing
• Predictive & Presymptomatic Testing
• Carrier Testing
• Prenatal Testing
• Newborn Screening
• Pharmacogenomic Testing
• Companion Diagnostic Testing

Sample Types Covered:

• Blood
• Tissue
• Saliva
• Buccal Swab
• Bone Marrow
• Cell-Free DNA (cfDNA)

Clinical Applications Covered:

• Oncology
• Rare Genetic Disorders
• Cardiovascular Diseases
• Neurological Disorders
• Infectious Diseases
• Reproductive Health
• Prenatal & Newborn Screening
• Metabolic Disorders
• Immunological Disorders

End Users Covered:

• Hospitals
• Clinical Laboratories
• Diagnostic Centers
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
• Saudi Arabia
• United Arab Emirates
• Qatar
• Israel
• Rest of Middle East
  • Africa
• South Africa
• Egypt
• Morocco
• Rest of Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

• 1.1 Market Snapshot and Key Highlights
• 1.2 Growth Drivers, Challenges, and Opportunities
• 1.3 Competitive Landscape Overview
• 1.4 Strategic Insights and Recommendations

2 Research Framework

• 2.1 Study Objectives and Scope
• 2.2 Stakeholder Analysis
• 2.3 Research Assumptions and Limitations
• 2.4 Research Methodology
  • 2.4.1 Data Collection (Primary and Secondary)
  • 2.4.2 Data Modeling and Estimation Techniques
  • 2.4.3 Data Validation and Triangulation
  • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

• 3.1 Market Definition and Structure
• 3.2 Key Market Drivers
• 3.3 Market Restraints and Challenges
• 3.4 Growth Opportunities and Investment Hotspots
• 3.5 Industry Threats and Risk Assessment
• 3.6 Technology and Innovation Landscape
• 3.7 Emerging and High-Growth Markets
• 3.8 Regulatory and Policy Environment
• 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

• 4.1 Porter's Five Forces Analysis
  • 4.1.1 Supplier Bargaining Power
  • 4.1.2 Buyer Bargaining Power
  • 4.1.3 Threat of Substitutes
  • 4.1.4 Threat of New Entrants
  • 4.1.5 Competitive Rivalry
• 4.2 Market Share Analysis of Key Players
• 4.3 Product Benchmarking and Performance Comparison

5 Global Genomic Medicine Market, By Product & Service

• 5.1 Sequencing Instruments
• 5.2 Reagents & Consumables
• 5.3 Bioinformatics Software
• 5.4 Genomic Testing Services
• 5.5 Clinical Interpretation Services

6 Global Genomic Medicine Market, By Technology

• 6.1 Next-Generation Sequencing (NGS)
• 6.2 Polymerase Chain Reaction (PCR)
• 6.3 Sanger Sequencing
• 6.4 Microarray
• 6.5 CRISPR Genome Editing
• 6.6 Fluorescence In Situ Hybridization (FISH)
• 6.7 Digital PCR (dPCR)
• 6.8 Long-Read Sequencing

7 Global Genomic Medicine Market, By Genomic Medicine Approach

• 7.1 Molecular Diagnostics
• 7.2 Precision Medicine
• 7.3 Pharmacogenomics
• 7.4 Gene Therapy
• 7.5 Gene Editing

8 Global Genomic Medicine Market, By Test Type

• 8.1 Diagnostic Testing
• 8.2 Predictive & Presymptomatic Testing
• 8.3 Carrier Testing
• 8.4 Prenatal Testing
• 8.5 Newborn Screening
• 8.6 Pharmacogenomic Testing
• 8.7 Companion Diagnostic Testing

9 Global Genomic Medicine Market, By Sample Type

• 9.1 Blood
• 9.2 Tissue
• 9.3 Saliva
• 9.4 Buccal Swab
• 9.5 Bone Marrow
• 9.6 Cell-Free DNA (cfDNA)

10 Global Genomic Medicine Market, By Clinical Application

• 10.1 Oncology
• 10.2 Rare Genetic Disorders
• 10.3 Cardiovascular Diseases
• 10.4 Neurological Disorders
• 10.5 Infectious Diseases
• 10.6 Reproductive Health
• 10.7 Prenatal & Newborn Screening
• 10.8 Metabolic Disorders
• 10.9 Immunological Disorders

11 Global Genomic Medicine Market, By End User

• 11.1 Hospitals
• 11.2 Clinical Laboratories
• 11.3 Diagnostic Centers
• 11.4 Academic & Research Institutes
• 11.5 Pharmaceutical & Biotechnology Companies
• 11.6 Contract Research Organizations (CROs)

12 Global Genomic Medicine Market, By Geography

• 12.1 North America
  • 12.1.1 United States
  • 12.1.2 Canada
  • 12.1.3 Mexico
• 12.2 Europe
  • 12.2.1 United Kingdom
  • 12.2.2 Germany
  • 12.2.3 France
  • 12.2.4 Italy
  • 12.2.5 Spain
  • 12.2.6 Netherlands
  • 12.2.7 Belgium
  • 12.2.8 Sweden
  • 12.2.9 Switzerland
  • 12.2.10 Poland
  • 12.2.11 Rest of Europe
• 12.3 Asia Pacific
  • 12.3.1 China
  • 12.3.2 Japan
  • 12.3.3 India
  • 12.3.4 South Korea
  • 12.3.5 Australia
  • 12.3.6 Indonesia
  • 12.3.7 Thailand
  • 12.3.8 Malaysia
  • 12.3.9 Singapore
  • 12.3.10 Vietnam
  • 12.3.11 Rest of Asia Pacific
• 12.4 South America
  • 12.4.1 Brazil
  • 12.4.2 Argentina
  • 12.4.3 Colombia
  • 12.4.4 Chile
  • 12.4.5 Peru
  • 12.4.6 Rest of South America
• 12.5 Rest of the World (RoW)
  • 12.5.1 Middle East
    • 12.5.1.1 Saudi Arabia
    • 12.5.1.2 United Arab Emirates
    • 12.5.1.3 Qatar
    • 12.5.1.4 Israel
    • 12.5.1.5 Rest of Middle East
  • 12.5.2 Africa
    • 12.5.2.1 South Africa
    • 12.5.2.2 Egypt
    • 12.5.2.3 Morocco
    • 12.5.2.4 Rest of Africa

13 Strategic Market Intelligence

• 13.1 Industry Value Network and Supply Chain Assessment
• 13.2 White-Space and Opportunity Mapping
• 13.3 Product Evolution and Market Life Cycle Analysis
• 13.4 Channel, Distributor, and Go-to-Market Assessment

14 Industry Developments and Strategic Initiatives

• 14.1 Mergers and Acquisitions
• 14.2 Partnerships, Alliances, and Joint Ventures
• 14.3 New Product Launches and Certifications
• 14.4 Capacity Expansion and Investments
• 14.5 Other Strategic Initiatives

15 Company Profiles

• 15.1 Illumina, Inc.
• 15.2 Thermo Fisher Scientific Inc.
• 15.3 F. Hoffmann-La Roche Ltd.
• 15.4 QIAGEN N.V.
• 15.5 Agilent Technologies, Inc.
• 15.6 Pacific Biosciences of California, Inc. (PacBio)
• 15.7 Oxford Nanopore Technologies plc
• 15.8 BGI Genomics Co., Ltd.
• 15.9 Revvity, Inc.
• 15.10 Exact Sciences Corporation
• 15.11 Guardant Health, Inc.
• 15.12 Natera, Inc.
• 15.13 Myriad Genetics, Inc.
• 15.14 GeneDx Holdings Corp.
• 15.15 Tempus AI, Inc.
• 15.16 NeoGenomics, Inc.
• 15.17 Personalis, Inc.
• 15.18 GRAIL, Inc.